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Background: While case series have established the efficacy of deep brain stimulation
(DBS) in treating obsessive-compulsive disorder (OCD), it has been our experience that
few OCD patients present without comorbidities that affect outcomes associated with
DBS treatment. Here we present our experience with DBS therapy for OCD in patients
who all have comorbid disease, together with the results of our programming strategies.
Methods: For this case series, we assessed five patients who underwent ventral
capsule/ventral striatum (VC/VS) DBS for OCD between 2015 and 2019 at the University
of Colorado Hospital. Every patient in this cohort exhibited comorbidities, including
substance use disorders, eating disorder, tic disorder, and autism spectrum disorder.
We conducted an IRB-approved, retrospective study of programming modifications and
treatment response over the course of DBS therapy.
Results: In addition to patients’ subjective reports of improvement, we observed
significant improvement in the Yale-Brown Obsessive-Compulsive Scale (44%), the
Montgomery-Asberg Depression Rating Scale (53%), the Quality of Life Enjoyment
and Satisfaction Questionnaire (27%), and the Hamilton Anxiety Rating scales (34.9%)
following DBS. With respect to co-morbid disease, there was a significant improvement
in a patient with tic disorder’s Total Tic Severity Score (TTSS) (p = 0.005).
Conclusions: DBS remains an efficacious tool for the treatment of OCD, even in
patients with significant comorbidities in whom DBS has not previously been investigated.
Efficacious treatment results not only from the accurate placement of the electrodes by
the surgeon but also from programming by the psychiatrist.
Keywords: psychiatric
DBS programming
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INTRODUCTION

In fact, stimulating different targets within the CSTC circuit
has been shown to have similar efficacy (12). VC/VS is the
most commonly reported target in the literature, followed by
the nucleus accumbens (NAc) and then others (13). Bilateral
targeting is performed in DBS surgery as the 2014 evidencedbased guidelines reported that there are insufficient data to
support unilateral targeting (14). DBS received a Humanitarian
Use Device (HUD) designation in 2009 under a Humanitarian
Device Exemption (HDE), meaning that it can be used to treat
“severe to extreme” refractory cases of OCD. An HDE is granted
for Humanitarian Use Devices (HUDs) that have been found to
be safe, have probable benefit, and are intended to be used in
<8,000 patients per year. HDEs are designed to bring hope to
those suffering severely who cannot wait for extensive large-scale
trials that would be required to demonstrate the effectiveness and
may never be feasible (15).
While previous studies have established that DBS for OCD
is likely to be a beneficial treatment for refractory severely
impaired patients, these studies have largely ignored how DBS
impacts (or does not affect) the other psychiatric diseases that
are so frequently comorbid with OCD (12). OCD rarely occurs
in isolation. For example, according to the DSM5, 76% of
patients with OCD also have a lifetime diagnosis of an anxiety
disorder such as panic disorder, generalized anxiety disorder, or
social anxiety disorder; 41% have a lifetime diagnosis of major
depressive disorder (MDD); 22% have a lifetime diagnosis of
a bipolar spectrum or depressive disorder other than MDD;
and 30% have a lifetime tic disorder. The DSM5 also states
that rates of OCD are elevated in those with eating disorders
and schizophrenia-spectrum disorders. Here we discuss our
DBS treatment of refractory OCD patients who have such
comorbid disease and our experiences with programming for
OCD while managing multiple symptoms of these other illnesses
and minimizing side effects.

Obsessive-compulsive disorder (OCD) is a debilitating disorder
characterized by obsessions and compulsions that afflicts ∼1.2%
of people in the United States and between 1.1 and 1.8%
worldwide (1). Obsessions are unwanted thoughts, urges, or
images that cause distress. Compulsions are repetitive behaviors
or mental “acts” (such as counting) that are performed to assuage
distress or to prevent a feared event from happening. Many
but not all compulsions make sense cognitively but consume
far more time than they would for someone without OCD.
For example, fear of contamination might lead to excessive
handwashing or fear of burning down the house might lead
to excessive checking of the stove. While there are different
severities of OCD, some people suffer extreme impairment to
the degree that they are unable to maintain regular employment
or enjoy everyday activities (2). There are five general subsets
of symptoms within OCD, including contamination obsessions
with washing/cleaning compulsions; harm obsessions with
checking compulsions, obsessions without visible compulsions;
symmetry obsessions with ordering, arranging, and counting
compulsions, and hoarding (3).
Treatment generally includes cognitive-behavior therapy
(CBT) with exposure and response prevention (EX/RP) alone
or a combination of EX/RP and medications such as selective
serotonin reuptake inhibitors (SSRIs), the tricyclic antidepressant
clomipramine, and/or antipsychotics (4, 5). Despite maximal
treatment, usually combining EX/RP with serotonergic and other
augmenting agents, it is seldom that patients with OCD are
able to achieve full remission, which is defined as a subclinical
score of ≤7 on the Yale-Brown Obsessive Compulsive Score
(Y-BOCS). Approximately 10% remain severely incapacitated
despite receiving EX/RP coupled with therapeutic medication
regimens (6). For these refractory patients, treatment options are
extremely limited.
Deep brain stimulation (DBS) involves a technique by which
stimulating electrodes are placed in the deep nuclei of the brain,
usually the ventral capsule/ventral striatum. The mechanism of
DBS in OCD has not been fully elucidated but is thought to
modify aberrant circuitry, including the cortico-striato-thalamiccortical (CSTC) circuit. Applied initially to intractable pain,
DBS is most commonly employed in movement disorders such
as Parkinson’s disease but has been used for the treatment of
OCD predicated on the understanding of the CSTC circuit’s
involvement in this disorder (7). The idea of applying DBS to
OCD grew out of observations that lesional procedures such as
anterior capsulotomy, utilized for the treatment of OCD since the
1950s, are about 50–60% effective in treating refractory patients
with the disorder (8–10). However, whereas lesional procedures
create enduring changes in the brain by permanently destroying
tissue and irreversibly interrupting circuits, DBS is a reversible
and titratable form of neuromodulation.
The first case of DBS for refractory OCD was performed in
1999 in the anterior limb of the internal capsule (ALIC; the
same target as in anterior capsulotomy) before being further
refined to the ventral capsule/ventral striatum (VC/VS). Both the
AC and VC/VS participate in the same CSTC circuit (10, 11).
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METHODS
Between 2015 and 2019, five patients were implanted bilaterally
with 4-contact electrodes (Model 3391, Medtronic, Minneapolis,
MN) targeting the VC/VS at our institution by a single surgeon
(AA) after approval by an interdisciplinary ethics conference
as advised in the literature (16). Three cases were done awake
with microelectrode recording and intraoperative testing by
a single psychiatrist (RD), and the remaining two patients
elected for an asleep protocol using an MRI-guided direct
targeting technique. Consensus coordinates were utilized for
initial targeting; however, the targets were ultimately refined
directly based on each patient’s individual images. The indirect
targeting anatomic coordinates used were 7–10 mm lateral to
the midline on the X axis, 0–5 mm anterior to the anterior
commissure (AC) in the Y axis, and 1–5 mm inferior to the
inferior border of the AC in the Z axis. In all cases, the target
was advanced by 3 mm (the depth of one contact) after the
identification of the direct target to allow for the space between
contacts 0 and 1 to rest at the junction of the anterior limb of
the internal capsule (ALIC) with the anterior limb of the AC. All
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contact using a frequency of 135 and the pulse width value that
yielded the best response during the monopolar survey. Widge
et al., suggest using (0–, 1–, 3+) and (1–, 2–, 3+) (17). The
psychiatrist in this report used (0–, 3+), (1–, 3+), (2–, 3+)
or the combination of 2 cathodes as suggested by Widge et al.
depending on patients’ response during the monopolar survey
(17). On day three, the psychiatrist selected the settings at which
the patient had the best response and made minor adjustments as
needed, such as increasing or decreasing amplitude, decreasing
frequency (e.g., to target increased anxiety), or decreasing or
increasing pulse width (e.g., if a patient had more improvement at
150 microseconds but also more adverse effects, an intermediate
pulse width could be selected).

patients returned at least 1 week after cranial lead implantation
for placement of bilateral extension cables and pulse generators.
There were no associated surgical complications. Rating scales
were performed by a single psychiatrist (RD) who was also the
primary programmer; when multiple scales were available from
pre-operative assessment, they were averaged for the sake of our
analysis. We have from 1 to 4 years of follow-up for each patient.
Patients provided informed, written consent for this retrospective
case report and reviewed the material described in this report; in
addition, all efforts have been made to preserve anonymity.

Calculation of Charge Density
For monopolar configurations, charge density was calculated
with the standard approach:
Charge density = (current ∗ PW)/surface area. For bipolar
configuration, charge density was calculated by dividing the
current at the cathode and anode.

Statistical Analysis for Diagnostic Rating
Scales

For each patient, using pre-operative MRI, expert identification
of the AC-ALIC junction was localized to the axial plane at
the optimal level for the AC. Following co-registration of the
pre-operative MRI with the post-operative CT (in cases 2–5) or
post-operative MRI (case 1), the ventral-most point of the lead
artifact was localized. Next, for each patient, the final followup active contacts were used to estimate the location along the
lead artifact for localizing the active contact in the CT space.
For a monopolar setting, the midpoint of the contact was used;
for bipolar or double monopolar settings, the midpoint between
the contacts was used as the active contact location. Finally, the
distance in mm between the active contact location along the
electrode artifact and the AC-ALIC junction was measured.

For all five patients, the following scales were assessed before DBS
surgery and at every programming session after implantation:
the Yale-Brown Obsessive Compulsive Scale (Y-BOCs), the
Montgomery-Asberg Depression Rating Scale (MADRS), the
Hamilton Anxiety Rating Scale (HAM-A), and the Quality
of Life Enjoyment and Satisfaction questionnaire (Q-LES-QSF), and the Young Mania Rating Scale (YMRS). Individual
cases exhibited comorbidities that were assessed with relevant
scales: Case 1, with a history of anorexia nervosa, assessed with
Eating Disorder Examination 16.0 (19); Case 2, with a history
of tic disorder, assessed with Yale Global Tic Severity Scale
(YGTSS) (20); Case 4, had comorbid substance use which was
assessed substance craving scales for cigarettes, marijuana and
alcohol (21). Rating scale scores collected following DBS were
compared to the pre-surgical baseline by computing the percent
change. For each case, on each scale, the change from baseline
was statistically assessed by a univariate paired t-test between
the average pre-surgery and post-surgical assessment data. A
Bonferroni correction was for multiple comparisons (per scale,
the number of comparisons was equal to the number of cases).

Methodology for Programming

Case Vignettes

A single psychiatrist (RD) performed initial and ongoing
programming for all 5 patients. Initial programming took place
over three consecutive days, then weekly for several weeks,
followed by every other week for about 6 weeks, then monthly
with spacing to every 3 months once ideal settings were selected.
The programming algorithm described by Widge et al. (17) was
followed on the first 3 days, with adjustments to the algorithm
as needed based on patient response (e.g., titrating in smaller
increments for patient comfort or fine-tuning, not increasing to
6 V if the response was obvious at 4 V). Selection of parameters
was based on a reduction in anxiety, an increase in energy,
improvement in mood, the patients’ subjective experience, and
the programmer’s observations of the patient’s engagement and
affect (18). On day one, the psychiatrist performed a monopolar
survey at contacts 0, 1, 2, and 3 at amplitudes of 2, 4, and 6 V
with frequency of 135 and pulse width of 90 microseconds. This
was repeated at a pulse width of 150 microseconds and was done
separately for each hemisphere. On day two, the psychiatrist
performed a bipolar survey (with contact 3 as the anode) at each

Case 1

Measurement of Distance Between the
Active Contact(s) and the Anterior
Commissure (AC) – Anterior Limb of the
Internal Capsule (ALIC) Junction

Frontiers in Psychiatry | www.frontiersin.org

A 32-year-old woman with a 24-year history of OCD and
comorbid severe and enduring anorexia nervosa and severe
major depressive disorder (MDD) presented with a YaleBrown Obsessive-Compulsive Scale (YBOCS) rating of 36. Her
obsessions included fear of bad things happening (of which
one potential bad thing was weight gain), and her compulsions
included repeating things a certain number of times, organizing
and arranging, and reassurance seeking. Though she had
previously worked briefly as a registered nurse, she had been
institutionalized for much of her child and adult life. She had
one previous suicide attempt in 2013, and she continued to
experience persistent, passive suicidal thoughts. She had episodes
of self-harm, including an incident where she fractured her
hand 18 months prior to evaluation. She continued to engage in
self-harm when distressed, including scratching and excoriating
herself. She had failed numerous medications [8 adequate
trials of serotonergic medications, 7 atypical antipsychotics, 2
first generation antipsychotics, 2 monoamine oxidase inhibitors
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bizarre and irrational, he had good insight into this and did
not meet criteria for a primary psychotic disorder. He had tried
five different classes of medications, including 3 serotonergic
medications including clomipramine at adequate dose and
duration, benzodiazepines, antipsychotics, stimulants, and mood
stabilizers. He had intravenous ketamine and underwent 40
sessions of deep transcranial magnetic stimulation (TMS) for
OCD with limited effect. He had previously undergone a
parathyroidectomy (pathology: normal) in attempt to ameliorate
his symptoms; however, this did not result in the desired
functional improvement. He subsequently elected to proceed
with asleep-protocol bilateral placement of VC/VS electrodes.

(MAO-Is), 4 benzodiazepines, intranasal ketamine, and multiple
augmenting agents] and electroconvulsive shock therapy. She
elected to proceed with awake placement of bilateral VC/VS
electrodes, and intraoperative exposure included the soft drink
Coca-Cola, the candy Tootsie Pop, and the color red, to all of
which she had an aversion.

Case 2
A 46-year-old man with a 25-year history of OCD together with
autism-spectrum disorder, tic disorder, and MDD had failed 5
serotonergic medications including clomipramine at adequate
dose and duration with appropriate augmenting strategies prior
to presenting with a YBOCS of 39. His main obsession was
that he was not seeing things correctly, and his compulsions
included staring and checking. Despite doing well in advanced
classes in high school, he was not able to finish higher education
or maintain a job and thus elected to proceed with asleep
direct targeting protocol placement of bilateral VC/VS electrodes.
Details regarding Case 2 were previously published (22).

Programming
Patient 1
This patient agreed to remain in whatever level of care was
necessary to maintain ideal body weight during the first year of
DBS programming, which was ultimately residential treatment.
Positive effect on mood and energy was partially maintained
by turning down amplitude bilaterally at night. Currently,
stimulation amplitude is set higher relative to the other patients
in this cohort, and the authors postulate this is due to two factors:
(1) severe, profound depression at baseline [highest score on
MADRS of the 5 patients – 41.67 mean pre-operative score vs.
29.67 (#2), 28.5 (#3), 30 (#4), and 35.5 (#5)] and (2) less obvious
response to stimulation led to continued titration.

Case 3
The third patient was a 28-year-old man with a 19-year history
of OCD together with attention deficit/hyperactivity disorder
(ADHD), MDD, and a previous history of cannabis use disorder
who failed multiple medications and augmenting strategies,
including three trials of serotonergic medications at adequate
dose and duration (one of which was clomipramine) and
subsequently presented for treatment with a YBOCS of 32. His
obsessions included disgust related to fast food, people who ate
fast food, American cars, and anything/anyone from the East or
the South. His compulsions including cleaning and washing. He
had to withdraw from his graduate program but remained highly
motivated to “be better.” He underwent staged, awake placement
of bilateral VC/VS electrodes.

Patient 2
Programming was complicated by this patient’s autism spectrum
disorder leading to difficulty describing his internal mood and
anxiety states. He disliked any obvious changes so amplitude was
increased very gradually, and frequency was lowered to 100 Hz.

Patient 3
The left electrode was pulled back post-operatively due to
imaging showing it was abutting the internal carotid artery. There
was still noted benefit during initial programming, but the patient
felt the effect was less noticeable than the right. This patient
experienced dramatic reduction in YBOCS and improvement in
mood in the first week (YBOCS: 9 = 72% reduction; MADRS: 12
= 58% reduction; YMRS = 1) with R hemisphere: case +/0–/1–;
3.5 V; 135 Hz; 150 µs and L hemisphere: case +/0–; 4 V; 135 Hz;
150 µs. To this patient’s dismay, these effects did not last, and
his Y-BOCS increased back to 24 (27% reduction from baseline)
and MADRS to 32 (12% increase from baseline) by the second
week. He was quite disappointed for several months, hoping the
psychiatrist would do something to bring back those feelings. His
MADRS peaked at 37 (30% increase from baseline) with a YBOCS of 18 at 7 weeks post-stimulation. At this point, low-dose
olanzapine (2.5 g) was added, leading to marked improvement
in OCD and depression symptoms. MADRS declined to 11 at
14 weeks post-stimulation with a Y-BOCS of 16, then increased
again to MADRS of 31 and Y-BOCS of 22 at 32 weeks poststimulation after a month’s trial of reduction in pulse width from
150 to 120 µs (reduced due to patient feeling jittery and agitated
at amplitudes higher than 2 V on the right). Mood and OCD
symptoms improved with increase back to 150 µs bilaterally,

Case 4
A 48-year-old male had been diagnosed with OCD at age 24 by
a priest because he presented compulsively to confession. At the
time of presentation, he had a YBOCS of 32 after having failed 3
serotonergic medications at adequate dosage and duration and 2
antipsychotics. His obsessions included a fear of displeasing God,
a fear of going to Hell, and a fear of his mother being in Hell.
His compulsions included praying and moving in certain ways.
He had comorbid MDD, insomnia, and issues with substance use
[nicotine use disorder, daily cannabis use, and heavy alcohol use
– as defined by the NIAAA (23)]. He was working in construction
at the time of surgery. He underwent staged, awake placement of
bilateral VC/VS electrodes.

Case 5
The most recently operated patient is a 42-year-old man with a
23-year history of OCD with comorbid MDD and social anxiety
disorder who presented with a YBOCS of 36. His obsessions
included a fear that inanimate objects were watching him play
video games and that if he saw people moving or speaking,
this would mean he wouldn’t be able to move or speak in the
future. He recognized the illogical nature of these thoughts and
referred to them as “psychotic.” Though patient’s obsessions were

Frontiers in Psychiatry | www.frontiersin.org
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which pleases his mother who is worried about his ability to be
independent once she dies.

and he limited amplitude on the right to 2.6 V or less when in
monopolar configuration. He has been on stable settings for the
past 7 months and switches the right settings between monopolar
(case+/1–; 2.4-2.6 V; 150 µs; 135 Hz) for sleep to bipolar (0+/1–;
5 V; 150 µs; 135 Hz) for work, school, or driving. He keeps the
left at C+/2–; 4.0 V, 150 µs, 135 Hz.

Patient 3
He began a healthcare management graduate programming and
did very well but decided that was not the career path for
him. He is currently thriving in a new graduate program for
architectural design.

Patient 4
This patient experienced transient improvement in OCD
symptoms (29% reduction in Y-BOCS at 16 weeks) with
relapse to 1 point higher than baseline at 3 weeks. He
experienced marked dysphoria and irritability when pulse
width was increased to 210 at 28 weeks post-stimulation.
This resolved with temporary addition of olanzapine 5 mg
(at 32 weeks) and decrease back to a pulse width of 150.
At 71 weeks, patient’s Y-BOCS had decreased to 25, and he
described his remaining compulsions as reflexive and habit-like.
The psychiatrist conceptualized his residual movement-related
compulsions as “tourettic” (24), so haloperidol was added and
titrated to 5 mg at bedtime. The patient experienced a marked
reduction in Y-BOCS to 16 over the next 8 weeks without further
change to DBS parameters.

Patient 4
Sustained improvement has only been recent, and he is struggling
to determine how to fill his day, given that much of his
time was previously occupied by compulsions. He recently
started working as a history teacher and is finding this very
challenging to do virtually (due to the pandemic and in-person
learning restrictions).

Patient 5
He is thrilled at his ability to play video games without intrusion
from OCD, he took a drawing class, and he has resumed
playing in a racquet-ball league. He is considering whether he
would like to find a volunteer position vs. apply for a job as a
staff accountant.

Patient 5

Diagnostic Scale Analysis

This patient experienced early, marked improvement at low
amplitude and pulse width. He began to experience hypomania
with marked irritability at (R: case +/1–; 2.7 V; 90 µs; 135 Hz and
L: C+/0–; 2.7 V; 90 µs; 135 Hz). Attempts to taper paroxetine
(decrease from 80 to 60 mg/day) led to increase in intrusive
thoughts. Patient did not tolerate trials of valproic acid and
lithium. Irritability and hypomania remitted with change to
bipolar settings at 21 weeks post-stimulation (R: 0–/3+; 4.5 V;
90 µs; 135 Hz and L: 0–/3+; 4.2 V; 90 µs; 135 Hz), but patient
did not find this as effective for his OCD. Ultimately, he remains
on monopolar settings without hypomania and manages building
irritability by switching to bipolar settings (usually once or twice
a day). He specifically changes to bipolar before driving because
he recognizes this is a time where he is more prone to irritability,
and he also switches to bipolar for sleep.

Five diagnostic scales were applied to all cases: Y-BOCs, MADRS,
and the Q-LES-Q-SF, HAM-A, and YMRS. The median poststimulation change as a percent of baseline, across all cases
for Y-BOCs, was −44% (IQR = 44%) and at final follow-up
the mean percent change was −49.1%; MADRS, the median
change was −53% (IQR = 49%) and at final follow-up the
mean percent change was −54.1%; Q-LES-Q, DBS resulted in
a median increase of 27% (IQR = 68%) in perceived quality
of life and satisfaction and at final follow-up the mean percent
change was 37.6%; YMRS, DBS induced a median increase
of 100% and at final follow-up the mean percent change was
32.4%; HAM-A, DBS induced a median reduction of −51%
and at final follow-up the mean percent change was −35.0%
(Figure 1A). For individual cases, a varying number of poststimulation parameter adjustments were required to achieve
optimal response. Figure 1B shows that most patients showed
significant improvement in MADRS, HAM-A and YMRS, by
around 100 days post-stimulation, whereas both Q-LES-Q-SF
and Y-BOCS required more than 250 days for at least 3 of
the cases to achieve peak change from baseline. Variation in
response to programming was also evident as a function of time.
For Y-BOCS, most cases exhibited a significant improvement in
obsessive compulsive behaviors that persisted for the duration
of their documented therapy. Figure 2A depicts that 3 of the 5
cases exhibit over 50% improvement in YBOCs; however, there
are slight fluctuations between 40 and 60% improvement likely
modulated by changes in programming parameters. Despite
fluctuations, all 5 cases show a trajectory toward improvement
as therapy progresses. Figure 2B highlights the change over time
in Q-LES-Q-SF response. For this quality-of-life measurement,
4 out of 5 cases (P2–P5), show marked improvement either at
the outset of stimulation (P4 and P5) or as function of changes

RESULTS
Anecdotal Evidence
Patient 1
Despite persistent low BMI of 14, she has remained out of the
hospital for 29 months, the longest time period since onset
of OCD and anorexia. She is working part time as a research
assistant, is active in her church, and, though she wishes for
further reduction in symptoms, she notes her quality of life and
mood is better than prior to DBS. In addition, she no longer
engages in self-injurious behaviors and no longer experiences
suicidal ideation.

Patient 2
Patient has been volunteering regularly and is happy to find that
others enjoy working with him. He has returned to school and
learned computer and basic life skills (e.g., doing online banking),
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FIGURE 1 | (A) Violin plots showing group level representation of the percent change from pre-DBS surgery baseline across the five mood disorder scale metrics
used for our cohort: Hamilton Anxiety Rating Scale (HAM-A), Montgomery-Åsberg Depression Rating Scale (MADRS), Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q-SF), Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Young Mania Rating Scale (YMRS). Dots represent post-surgery DBS programming
sessions. Each scale plot represents all subjects and all post-surgery DBS programming sessions for the first year of follow-up. The solid line demarcates no change
(0%) on the y-axis, and the dotted line indicates the median percent change. Red points indicate percent change in scale metrics for each individual patient from the
final follow-up and the red dotted line represents the mean for all patients for the final follow up. (B) Individual and scale differences in the number of programming
sessions necessary to achieve optimal therapeutic stimulation. Each scale plot denotes the number of days required to achieve optimal stimulation for each patient
highlighted by a different color.

response during the initial 200 days of stimulation; however, it
rebounds back to the pre-stimulation baseline during the latter
half of therapy. There is no effect of DBS on marijuana craving
overall; however, during many sessions, DBS appears to increase
craving. Finally, in Figure 3E, tobacco craving (measured using
a cigarette craving rating scale) shows the most lasting response
to DBS, with both an immediate and sustained drop in craving
by 30%.

in programming parameters (P2 and P3). Finally, Figure 2C
shows that improvement in MADRS is immediate and invariant
over time in 3 out of 5 cases. P1 shows no change and no
fluctuations, and P3 shows an immediate improvement that
gradually increases over time.

Comorbid Scale Analysis
Specific cases in this OCD cohort exhibited comorbid symptoms
that in other OCD-DBS reports have responded to DBS. Case
2 had a history of tic disorder manifestations and was assessed
pre- and post-surgical using the YGTSS and sub-scale Total
Tic Severity Score (TTSS). Figures 3A,B show that TTSS did
not significantly change from pre-surgical baseline (p = 0.22);
however, YGTSS did show a significant reduction that was more
marked following initial programming (p = 0.005). Case 4 was
diagnosed with nicotine use disorder, at risk alcohol use, and
daily cannabis use. To assess whether DBS affected the patient’s
craving for these substances, we measured craving pre- and
post-surgery. Figures 3C–E depict Case 4’s craving response
following DBS. Alcohol craving in Figure 3C shows a marked

Frontiers in Psychiatry | www.frontiersin.org

Charge Density Calculated for the Final
Follow-up
All patients in this cohort experienced improvement in their
OCD symptoms as measured by change in Y-BOCS, however
the stimulation parameters and selected therapeutic contacts at
final follow-up varied across patients. To determine whether an
association between anatomical location of therapeutic contacts
and tissue activation as measured by charge density, we analyzed
the relationship between charge density and distance between the
AC-ALIC junction and the mid-point of the active contact(s).
We found that the lower the charge density was negatively
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FIGURE 2 | The individual time course representation for patient response to DBS programming modifications across the five mood disorder scale metrics. (A)
Hamilton Anxiety Rating Scale (HAM-A). (B) Montgomery-Åsberg Depression Rating Scale (MADRS). (C) Quality of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q-SF). (D) Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). (E) Young Mania Rating Scale (YMRS).

without intervention within 1–2 days. Patient 3 had hypomania
and sympathomimetic effects including flushing, tachycardia,
and hypertension. Patient 4 had dysphoria and irritability at
a pulse width of 210. Patient 5 experienced hypomania with
irritability and aggression.

correlated with the distance between the AC-ALIC junction
and the active contact(s); r = −0.58, p = 0.037 (see Figure 4
and Table 1).

Adverse Events
Some adverse events were encountered during programming, but
these were all temporary. Hypomania was the most encountered
adverse effect. Patient 1 had jaw tightening and pulling and
tongue tingling. Patient 2 experienced transient hypomania and
insomnia after an increase in amplitude, and this resolved

Frontiers in Psychiatry | www.frontiersin.org

DISCUSSION
While the efficacy of DBS for OCD has been well-established,
there are few reports of success in patients with comorbidities,
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FIGURE 3 | Patient specific comorbidities. (A,B) A patient (P2) had a comorbid autism-spectrum disorder, tic disorder, which was measured at each DBS
programming session using the (A) Total Tic Severity Score and the (B) Yale Global Tic Severity Scale (C–E). A patient (P4) had comorbid substance use (nicotine use
disorder, daily cannabis use, and at-risk alcohol use), which was measured at each DBS programming session using craving scales for ETOH (C), marijuana (D), and
cigarettes (E).

so high quality recommendations are not available, though
1-year results of an open label trial at University of Toronto
for subcallosal cingulate stimulation demonstrate improvement
in body mass index and affective symptoms (30). Comorbid
anorexia and OCD have previously been treated by both
anterior capsulotomy or VC/VS DBS with improvement in both
disorders (31, 32).

despite the reality that most patients have comorbid psychiatric
diagnoses in addition to OCD (25). Here we report the
results of VC/VS DBS in five patients whose comorbidities
include substance use disorders, MDD, autism spectrum
disorder, psychosis, anorexia nervosa, and tic disorder. A
recent study of quality of life QOL in OCD demonstrated
that QOL in OCD is often as dependent on the comorbid
psychiatric disease as the OCD itself (26). This underscores
the fact that “success” from DBS in these patients is
heavily dependent on their comorbidities in addition to
their OCD.

Autism
Case reports have demonstrated improvement in both YBOCS
and autism spectrum disorder (ASD) in a patient with co-morbid
OCD and autism who underwent stimulation of the NAc (33)
and of another patient whose NAc was targeted for isolated selfinjurious behavior (SIB) in the setting of ASD (34). Other targets
reported for SIB in ASD include the basolateral amygdala (35),
globus pallidus interna (GPi), and GPi together with ALIC (36),

Anorexia
DBS has been performed for anorexia since 2010, when Israel
et al. targeted the subgenual cingulate cortex (27). Other targets
include the NAc and the bed nucleus of the stria terminalis
(28, 29). These studies have been case reports and case series,

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 4 | DBS electrode placement. (A) For each patient, localization of the bilateral DBS leads is visualized in the axial plane at the level of the anterior commissure
(AC) – anterior limb of the internal capsule (ALIC) junction; marked in yellow. Axial slices depict co-registered pre-operative MRI and post-operative CT for cases 2–5
and co-registered pre- and post-operative MRI for case 1. Hyperintense circular artifacts in cases 2–5 represent the DBS lead from the post-operative CT; the
hypointense circular artifacts in case 1 represent the DBS lead. Note that the axial images depicting lead location at the junction between AC and ALIC, do not
necessarily depict the location of the active contact. (B) Visualization and analysis of the association between the distance from the active contact(s) at final follow-up
to the AC-ALIC junction and charge density. A significant negative correlation was observed for the relationship between distance between the active contact(s) and
the AC-ALIC junction and charge density (p = 0.037, r = −0.58).

Netherlands, discontinuation of therapy during the crossover
phase resulted in reemergence of symptoms (41). Fifty percent
response and 30% remission was noted in open-label longterm follow-up of 28 patients receiving subcallosal cingulate
stimulation (42). Other targets being investigated for TRD
include superolateral branch of medial forebrain bundle and
lateral habenula.

with improvement in the first two cases but only temporary
improvement in the third.

Tourette’s
DBS has been studied in Tourette syndrome more robustly.
About 200 cases have been reported in the literature, and five
randomized controlled trials comprising a total of 43 patients
have been reported (37). However, the optimal target for
Tourette’s is still the subject of ongoing debate, as 10 different
regions have been suggested in the aforementioned studies,
including the GPi (anteromedial and posteroventrolateral
portions), the globus pallidus externus, the NAc, the ALIC,
the subthalamic nucleus (STN), and four regions within the
centromedial thalamus. A recent multi-institutional retrospective
study aimed to determine whether one target is superior to others
in resolving tics. The study did not find that one target was
superior to others for resolution of tics, but it did find that
regions superior, medial, or within the GPi were associated with
greater improvement in co-morbid OCD symptoms than those
inferior (38).

ADHD
No trials of DBS for ADHD have been performed.

Substance Use Disorder
Most work regarding DBS for addiction remains in translational
stages. While NAc is the most commonly considered target,
the lateral hypothalamus, medial prefrontal (PFC) cortex, STN,
lateral habenula, and insula have also been targeted with
promising results in animal models (43).

Psychosis
The ventral portion of the CA1 region of the hippocampus, PFC,
ventral striatum, NAc, substantia nigra, and ventral tegmental
area have been posited as potential targets in schizophrenia
(44, 45).
DBS of the VC/VS and NAc has been found to be slightly
less effective than lesional anterior capsulotomy for OCD in a
literature review, though the groups compared were not exactly
analogous since those treated with DBS were more likely to have
more severe disease and for a longer time, but it seems that
the modulatory nature of DBS makes it more socially acceptable
in the fraught world of psychiatric surgery than creation of a

Depression
DBS for treatment-resistant depression (TRD) has been the
subject of significant controversy. While open label studies
of VC/VS demonstrated promising results (39), a previous
randomized-controlled RECLAIM study on the subject was
halted early due to lack of significant difference between the
two arms after 30 patients had been enrolled (40). Interestingly,
in a RCT of 25 patients with bilateral VC/VS DBS in the
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TABLE 1 | DBS programming parameters.
Mean Y- BOCS score
pre-surgery

Patient 1:
35.33

Patient 2:
37.33

Patient 3:
32.67
(switches R side between
group A and B)

Patient 4:
31

Patient 5:
36
(switches between group
Aand group B)

6 months

R PG

(C+, 1–) 6.2 V/150
µs/100 Hz

L

(C+, 1–) 7.2/150
µs/100 Hz

R

(0+, 1–) 7 V/60
µs/100 Hz

L

(0+, 1–) 7 V/60
µs/100 Hz

R

(C+, 1–) 3.2 V/120
µs/135 Hz

Y-BOCS
reduction at 6 months

21% (28)
(7 mos)

62% (14)

57% (14)

Most recent

Y-BOCS
reduction at last
follow-up

R

(C+, 0–, 1–) 8 V/120
µs/135 Hz
15.5mA

L

(C+,0-,1-)
6.7V/150µsec/135Hz
12.8mA

R

(0+, 1–) 6.5 V/100
µs/100 Hz
6.5mA

L

(0+, 1–) 5.0 V/100
µs/100 Hz
5.0mA

R
A

(C+, 1–) 2.6 V/150
µs/135 Hz
4.9mA

R
B

(0+, 1–) 5 V/150
µs/135 Hz 5.9mA

L

(C+, 2–) 4 V, 150
µs/135 Hz 6.0mA

R

(C+, 0–, 1–) 4 V/150
µs/135 Hz
8.9mA

1,434 d

26%
(27)

961 d

49%
(19)

601 d

66%
(11)

562 d

48%
(16)

58%
(15)

L

(C+, 2–) 4.4 V/120
µs/135 Hz

R

(C+, 1–) 5.5 V/210
µs/135 Hz

L

(C+, 0–) 5.5 V/210
µs/135 Hz

L

(C+, 0–, 1–) 3.5 V/150
µs/135Hz
8.0mA

R
A

(0–, 3+) 4.5 V/90 µs/135 Hz 69% (11)

R
A

(0–, 3+) 4.5 V/90 µs/135Hz 266 d
3.8mA

L
A

(0–, 3+) 4.2 V/90
µs/135 Hz

L
A

(0–, 3+) 4.2 V/90
µs/135 Hz
3.3mA

R
B

(C+, 1–) 2.7 V/90
µs/135 Hz

R
B

(C+, 1–) 2.7 V/90
µs/135 Hz
3.8mA

L
B

(C+, 0–) 2.7 V/90
µs/135 Hz

L
B

(C+, 0–) 2.7 V/90
µs/135 Hz
2.9mA

19% (25)

R/L, Right/Left pulsegenerator. Bold values indicate therapeutic current.

Challenges of Programming

permanent lesion (10). Side-effect profiles were similar in both
groups. However, as our ability to identify connectivity pathways
improves, so too may we be able to predict which patients are
the most likely to respond positively to DBS: recent hypotheses
focus on the medial and lateral PFC and frontothalamic radiation
(46). Another recent study has demonstrated that PFC-related
cognitive control, including theta oscillations, improves after
DBS of VC/VS (47).
In previous meta-analysis, obsessions and compulsions with
sexual and/or religious content are more likely to respond to DBS
than other types of compulsions (12). It has also been posited that
CBT post-operatively may augment the efficacy of DBS; however,
this has only been demonstrated preliminarily in an open-phase
trial (48).

Frontiers in Psychiatry | www.frontiersin.org

This case series highlights many challenges that psychiatrists
may face during programming. Patients may feel markedly
improved with initial programming (particularly with regards
to mood), and, unfortunately, this degree of improvement does
not always persist. This may lead patients to feel disappointed
and “chase” the good feeling. To limit the chance of this,
the primary programmer has learned to increase amplitude
very gradually and only to test higher amplitude during initial
programming if response is not evident at lower amplitudes.
Programming is more difficult in patients who do not have
a good awareness of their internal states or emotions. The
programmer may need to rely on more objective observations:
for example, increased talkativeness, changes in affect, and
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patient #4 had residual tic-like compulsions that did not
respond to DBS but did respond to addition of an antipsychotic
(when a previous trial of an antipsychotic had not been
effective). In summary, though an initial algorithm may be
followed, DBS programming must be individualized to each
patient, and the programmer must be flexible and creative
in order to maximize clinical response while minimizing
adverse effects.
Finally, while every effort was made to maintain objectivity,
we recognize that our un-blinded status and the lack of a control
arm are major limitations to our study. Nonetheless, we feel
our case series data are worth sharing given the dearth of
co-morbid psychiatric disease in more formal studies of DBS
for OCD.

degree of indecision. It is useful to have friends and/or family
members in the room during programming as this allows for
more natural conversation and observation of interactions. It
can be helpful to discuss a topic of interest to the patient
in order to observe his or her level of interest, engagement,
and spontaneity. Additionally, patients with OCD often have
trouble making decisions, and providing self-ratings during
programming is no exception. Some patients have tended to
rate their symptoms (on a scale of 0–10) in increments of
0.25, not wanting to mistakenly over-report changes. Again,
the programmer can rely on more objective observations in
these cases.
Another challenging aspect of programming is that sometimes
patients experience adverse effects at the settings associated
with most clinical improvement, such as feeling physically
anxious, being more irritable, experiencing insomnia, or having
sympathomimetic effects. As described above, one patient
manages increased irritability by changing settings depending on
context. Another patient changes settings for sleep. Psychiatrists
may need to add medication for insomnia. Adjustments to
pulse width and frequency may mitigate adverse effects in
some patients. The programmer must allow adequate time
between changes in settings so that effects from a previous
setting do not carry over to the next setting. Sometimes
a change is very clear, and the programmer can make
changes within 30–60 s. Other times, it is less clear, and
the programmer may have the patient take a break for 10–
20 min or so on one setting then do the same on another to
better compare.
As described above, some patients were able to change
from one setting to another in order to mitigate side effects
or allow for sustained benefit. Other patients were not able
to do this effectively. For example, Patient 2 has not been
able to turn down DBS (or turn one hemisphere off) at
night due to a fear that he will do it incorrectly and “mess
up” his DBS. Patient 4 did not tolerate turning amplitude
down at night due to feeling significantly more depressed and
anxious. One patient (not included in this case series due to
having surgery after this manuscript was drafted) developed
compulsions related to her DBS, feeling the urge to repeatedly
turn DBS on and off in response to obsessions. Some patients
may be unable to manage changes appropriately using the patient
programmer initially but may be better able to do so farther
along the path of DBS programming as their OCD begins
to improve.
It is also important to keep in mind that DBS may not
mitigate all of a patient’s symptoms, but a patient may have
a better response to medication with DBS on. As described,

Conclusions
DBS has proven to be an efficacious treatment with an acceptable
side effect profile for treatment of refractory OCD. Here, we have
reported our institutional experience with five patients, all with
significant co-morbidities. Furthermore, we report programming
parameters, which have been seldom discussed in the literature.
While these represent only retrospective data, they aid in our
corpus of knowledge regarding bilateral VC/VS DBS for OCD
and underscore the need for more high-quality Level I evidence
regarding surgical management of OCD.
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